BazEkon - Biblioteka Główna Uniwersytetu Ekonomicznego w Krakowie

BazEkon home page

Meny główne

Autor
Bashlakova Ekaterina (Research Institute of the Public Health and Medical Managementof Moscow City Health Department), Holownia Malwina (Research Institute of the Public Health and Medical Managementof Moscow City Health Department), Solodun Ilya (Research Institute of the Public Health and Medical Managementof Moscow City Health Department), Evdoshenko Evgenyi (Research Institute of the Public Health and Medical Managementof Moscow City Health Department)
Tytuł
Optimization of Approaches to The Treatment of Metastatic Colorectal Cancer Wild-Type Gene KRAS
Źródło
Journal of Health Policy and Outcomes Research, 2015, nr 2, s. 79-87, tab., bibliogr. 29 poz.
Słowa kluczowe
Choroby nowotworowe, Leczenie, Leki, Optymalizacja
Cancer, Medical treatment, Drugs, Optimalization
Uwagi
summ.
Abstrakt
The results of the literature review of drug use for the treatment of metastatic colorectal cancer (mCRC) are presented. Analysis of the data showed that cetuximab (Erbitux) and panitumumab (Vectibix) are effective drugs for mCRC patients with KRAS wild-type in the first-line therapy, and the combination of standard chemotherapy regimen FOLFOX in combination with targeted therapy cetuximab (Erbitux) is the most optimal medical technology as compared with other combinations of chemotherapy and targeted drugs(original abstract)
Pełny tekst
Pokaż
Bibliografia
Pokaż
  1. Chibaudel C., Tournigand T. Therapeutic strategies in inoperable metastatic colorectal cancer. J. Clinical oncology. 2012; N.7 (3)
  2. All-Russian Union of Public Associations Association of oncologists of Russia: Epidemiology of Colorectal Cancer [cited 2.11.2015]. Available from: http://www.oncoproct.ru/expert/261
  3. Belyaeva АV. A mutation in the KRAS gene in patients with colorectal cancer: epidemiology and clinical significance: the thesis abstract on scientific degree of medical sciences: 14.01.12 /Belyaeva Anna Valerevna, Sankt-Peterburgo 2012; 23
  4. Schwartzberg LS., Rivera F., Karthaus M. et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol. 2014; 32: 2240-2247
  5. Vorobiev PА., Avksenteva МV., Borisenko ОV. et al. Clinical and economic analysis. Newdiamed, Moscow 2008; 778
  6. Van Cutsem E., Twelves C., Cassidy J. et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J. Clin. Oncol. 2001; 19: 4097-4106
  7. Bokemeyer C., Bondarenko I., Makhson A. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2009; 27: 663-671
  8. Colucci G., Gebbia V., Paoletti G. et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J. Clin. Oncol. 2005; 23: 4866-4875
  9. Saltz LB., Clarke S., Diaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 2008; 26: 2013-2019
  10. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004; 350: 2335-2342
  11. Kabbinavar FF., Schulz J., McCleod M. et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer. Results of a randomized phase II trial. J. Clin. Oncol. 2005; 23: 3697-3705
  12. Tebbutt NC., Wilson K., Gebski VJ. et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J. Clin. Oncol. 2010; 28: 3191-3198
  13. Bokemeyer C., Kohne C. et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur. J. Cancer. 2015; 51 (10): 1243-52
  14. Tveit K., Guren T., Glimelius B. et al. Randomized phase III study of 5-flurouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line therapy of metastatic colorectal cancer: the NORDIC VII study (NCT0014314), by the Nordic Colorectal Cancer Biomodulation Group. J. Clin. Oncol. 2011; 29 (4): abstract 365
  15. Miguel J. et al. Role of cetuximab in first-line treatment of metastatic colorectal cancer. Word J. Gastroenterol. 2014; 20 (15): 4208-4219
  16. Highlights of prescribing information to use Erbitux safely and effectively. [cited 5.11.2015]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s225lbl.pdf;
  17. Maughan TS., Adams RA., Smith CG. et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114
  18. Miroddi M., Sterrantino C. et al. Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: a meta-analysis of 18 randomized controlled clinical trials. Crit. Rev. Oncol. Hematol. 2015
  19. Tol J., Koopman M., Cats A. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 2009; 360: 563-572
  20. Douillard JY., Siena S., Cassidy J. et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 2010; 28: 4697-4705
  21. Peeters M., Karthaus M., Rivera F., Terwey J., Douillard J. Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status. J. Drugs. 2015; 75(7): 731-748
  22. Peeters M., Price T., Hotko Y., et al. Randomized phase 3 study of panitumumab (pmab) with FOLFIRI compared to FOLFIRI alone as second-line treatment (tx) for metastatic colorectal cancer (mCRC): Secondary endpoint results. Presented at: 12th World Congress on Gastrointestinal Cancer. Barcelona, Spain 2010
  23. Peeters M., Price TJ., Cervantes A. et al. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. J. Clinical Oncology. 2010; 28:31: 4706-4713
  24. Huxley N. The clinical effectiveness and cost-effectiveness of cetuximab (partial review of TA240) for previously untreated metastatic review and economic evalution. Assessment Report. 2015 [5.11.2015]. Available from: https://www.nice.org.uk/guidance/GID-TAG470/documents/colorectal-cancer-metastatic-cetuximab-review-ta176-and-panitumumab-part-review-ta240-1st-line-id794-assessment-report2;
  25. Zhu YL., Lou J. et al. A meta-analysis of cetuximab plus oxaliplatin based chemotherapy regimen for metastatic colorectal cancer. Indian. J. Cancer. 2014; 51 (3):7: 113-116
  26. Wang Q., Qi Y. et al. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumor Biol. 2015; 35(5): 3471-82
  27. Kolbin АS., Orlova RV., Pavlish АV., Goryachkina KА., Livshits МS., Proskurin МА. Oxaliplatin in chemotherapy of colorectal cancer. 2011 [cited 5.11.2015]. Available from: http://www.rmj.ru/articles/onkologiya/Oksaliplatin_v_himioterapii_kolorektalynogo_raka/;
  28. The application for reimbursement and establishment of official selling price of the medicinal product Vectibix (panitumumab) in the framework of the drug program "treatment of advanced colorectal cancer: ICD-10 - C18-20." Verification analysis Nr: AOTM-OT-4351-7/2014, 2014. [cited 6.11.2015]. Available from: http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2014/057/AWA/57_AWA_OT_4351_7_Vectibix_[panitumumab]_2014.05.22.pdf;
  29. The application for reimbursement and establishment of official selling price of the medicinal product Erbitux (cetuximab)." Verification analysis Nr: AOTM-OT-4351-11/2014, 2014. [cited 6.11.2015]. Available from: http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2014/069/AWA/069_AWA_OT_4351_11_Erbitux_2014.06.18.pdf;
Cytowane przez
Pokaż
ISSN
2299-1247
Język
eng
URI / DOI
http://dx.doi.org/10.7365/JHPOR.2015.2.7
Udostępnij na Facebooku Udostępnij na Twitterze Udostępnij na Google+ Udostępnij na Pinterest Udostępnij na LinkedIn Wyślij znajomemu